© Copyright 2010 CollPlant1

Company Overview

June 28, 2010

Investors Meeting

Safe Harbour Statement

2

All statements, other than statement of historical facts, included in this presentation regarding

our strategy, future operations, financial position, future revenues, projected costs, prospects,

plans and objectives of management are forward looking statements. The words “believe”,

“anticipate”, “plan”, “expect”, “intend”, “may’, “project”, “will”, “would”, and similar expressions

are intended to identify forward-looking statements, although not all forward –looking

statements contain indentifying words. We cannot guarantee that we actually will achieve the

plans, intentions or expectations disclosed in our forward-looking statements and you should

not place undue reliance on our forward-looking statements.

Our statements of “belief” are based primarily upon our results derived to date from our

research and development, our research and development programs with animals, and

discussion with potential partners . We believe that we have a reasonable scientific basis upon

which we have made such statements. It is not possible, however, to predict, based upon

studies in vitro, in animal or human studies whether a new therapeutic agent will be proved

ultimately to be safe and/or effective in humans and approved for commercial use. We cannot

assure that the particular results expected by us will occur.

Except as required by law, we do not assume any obligation to update any forward looking

statements or statements of “belief”. We disclaim any intention or obligation to update or revise

any forward-looking statements or statement of “belief”, whether as a result of new information,

future events or otherwise.

All references to dollars in the presentation are to USD.

CollPlant’s Profile

Production of recombinant human collagen in

bioengineered plants

3

Development and manufacturing of raw collagen and

collagen-based products for medical applications

Substantial pipeline including soft and hard tissue

repair products for orthopedic applications and for

advanced wound care products

Weizmann Science Park, Ness Ziona, Israel and

Yesod Hama’ala, Israel

Founded in 2004, listed CLPT in TASE since 5/2010,

35 employees

Platform

Focus

Pipeline

Locations

Background

Collagen is the Most Abundant Biomaterial in Human Body• Collagen is the principal protein of the skin, tendons, cartilage, bone and

connective tissue.

• More than 1,000 medical devices in the market are based on collagen

4Source: Tissue Engineering Options for Ligament Healing, Joseph W. Freeman

A Diagram of Tendon/Ligament Organization

Co-Expression of 5 Genes by Transformation and Cross-Breeding, Generating a Stable Plant Line

5

Why Tobacco?

Green Production - the system is a safe alternative to

animal/mammalian expression systems (FDA register January 2007)

Tobacco is easily manipulated using known biotechnology practices

Tobacco produces large biomass, 4-6 weeks to mature plant

Tobacco is not in the food/feed chain (in-line with FDA regulations)

6

Collage rhTM collagenFrom Plant to Product

7

Cultivation

Harvest of leaves

Crude extraction

Protein purification

Final formulation

Proteolytic conversion

Farming of CollagenProducing Tobacco Plants in Israel

• Contract farmers grow tobacco in

greenhouses

• High return for the farmer, competitive

cost for CollPlant

• Advanced agriculture in Israel

contributing to increasing yields

• The varied climate zones of Israel

allow growing high quality collagen

year-round

• Scalability – fast with no capital

requirements

8

„ Bone, cartilage & meniscus repair„ Wound care„ Surgical meshes„ Vascular grafts„ Corneal shields„ Hemostasis„ Surgical sutures„ Drug delivery solutions

Industry is focused on supply of new, safer biomaterials*

* 2008 collagen & HA biomaterials – global strategic business report, March 2008 by Global Industry Analyst Inc.

Uses of Collagen-Based Products

9

CollPlant's Business ModelThree Growth Engines

10

CollaborationsSupply agreements with top-tier

companies;• Supply collagen-based components

to end products

ProductsCollagen-based products ( )

for soft and hard tissue repair;• Orthopedic & wound healing markets

• Strategic collaborations

Raw MaterialRaw material ( )

For research applications;• Tissue culture & tissue eng. research

Scalability of Collagen Production

11

Notes:

(1) Typical product requires 100 mg collagen

(2) Assuming improvement in collagen purification yield by a factor of 2 (2011) and by a factor of 4 (2012)

Vergenix™ Facilitates Proliferation of Human Primary Cells

Control

Puracol

Fibracol

Promogran

Vergenix

0

0.2

0.4

0.6

0.8

1

0

0.2

0.4

0.6

0.8

1

0.0

0.1

0.2

0.3

0.4

Human keratinocytes

Human Endothelial Cells

Human Dermal fibroblasts

Cell

pro

lifera

tion (

AU

)

*

*

*

Cells were seeded in low density and allowed to

proliferate on 6 mm scaffold discs for 72 h. WST-1

assay was used to quantify cell proliferation.

Collage membrane induces increased

human primary dermal cell proliferation

Collage membrane Control (cover-slip)

72 h Cell proliferation

12

13

Test Result

Systemic Toxicity Passed

Cytotoxicity Passed

Hemolysis Passed

Muscle Implantation Passed

Intracutaneous Passed

Endotoxins by LAL Passed

Maximization Sensitization Passed

Pyrogen (LAL) Passed

ETO Residuals Passed

ISO 10993 Biocompatibility Studies

Study conducted at NAMSA

CollPlant’s Roadmap

14Focus on Major Unmet Medical Need

2010 2011 2012

High Strength Matrices*

Composed of polymeric

core & collagen shell

Applications:

• Hernia meshes

• Heart valve leaflets

Composite Membrane

structures

Moldable Putty

Wound Dressing

Matrix

Flowable Wound

Matrix

Applications:

• Bone void filler

• Osseous defectsApplications:

• Tunneled wounds

• Surgical wounds

• Ulcers

• Draining wounds

Applications:

• Surgical wounds

• Ulcers

• Draining wounds

Vergenix-WD

Microspheres for sustain

release of BMP to augment

bone and soft tissue repair

Notes*:

1.Thin strong matrices for minimally invasive surgery

2.Can be produced in different geometries

cGMP

Capability

Scalability &

3rd party mfg.

Biodegradable Implant

for repair of rotator cuff tears

Vergenix-FG

Resilin

Video

Vergenix-B

Biodegradable Implant

for repair of ACL

New biomaterials with

unique physical properties

Vergenix™ Wound Dressing Sheet

• 510(k) submitted to FDA followedby RFD

• Supporting in-vivo study in pigsdemonstrated equivalence

• Human studies in Israel will belaunched in Q4, 2010

15

In development; optimization is on-going:

• Focus on cohesiveness, flowability and fluid absorption

• Supporting in-vitro models and analytical methods;

−Equivalence in supporting human cell proliferation to Integraflowable gel

• Small scale pilot in-vivo study shows jump start in wound healing

16

Vergenix™ Flowable Gel

• In development, optimization is ongoing, focus on cohesiveness osteoconductivity

• In-vitro models being designed

• CRO for in-vivo currently being identified

17

Vergenix™ Putty for Bone Repair

18

The Commercial Opportunity

Tissue Engineered Musculoskeletal ProductsPotential US Market Forecast

19Source: Medtech Insight, Tissue Engineering and Cell Transplantation:

Technologies, Opportunities and Evolving Markets in the US

Market SegmentPotential

patients, 2010

Projected

Average Price

($)

Potential

Market, 2010

($M)

Bone Repair & Replacement 1,650,000 4,500 7,425

Joint/Cartilage Repair & replacement 4,400,000 4,500 19,800

Ligament Repair & Replacement 880,000 2,700 2,376

Meniscal Repair & Replacement 990,000 2,500 2,475

Total 7,920,000 - 32,076

KneeRotator cuff ExtremitiesSpine

Bone Graft Market Segments$2.4B Market Size

20

Growth Factor ($870M, 36%)

Cell Based ($110M, 4%)Synthetics

($250M, 10%)

DBM($430M, 18%)

Allograft ($765M, 32%)

• Medtronic (90%)

• Stryker

• Osteocel

• Osiris

• Nuvasive

• Synthes

• Biomet

• Wright Medical

• Smith & Nephew

• RTI

• Kensey Nash

• DePuy

• Orthovita

• MTF

• LifeNet Health

• AlloSource

• Isotis

• RTI

• OsteoTech

Tissue Engineered Skin Replacements & SubstitutesPotential US Market Forecast

21Source: Medtech Insight, Tissue Engineering and Cell Transplantation:

Technologies, Opportunities and Evolving Markets in the US

Notes:

1. Ulcer types: Acute pressure, arterial, chronic pressure, diabetic foot & venous.

2. Other applications for skin substitutes include dermabrasion site treatment, fasciotomy site treatment, Mohs

surgery site treatment, skin graft donor site treatment, and traumatic wound repair.

Market SegmentPotential

patients, 2010

Projected

Average Price

($)

Potential

Market, 2010

($M)

Abdominal Wall repair Products 162,000 1,200 194

Breast Repair Products 37,100 1,200 45

Burn Treatment Products 30,900 3,000 93

Face, Head & Neck Reconstruction Products 78,750 1,200 95

Ulcer Treatmet Products 4,158,000 4,000 16,632

Products for Other Applications 104,000 1,200 125

Total 308,750 - 17,183

Hernia repairBreast repairUlcer treatment Neck reconstruction

The Commercial OpportunityOrthobiologics

22

Rotator cuff (325,000 US)ACL (250,000 US) Hand/Wrist tendons (115,000 US)

Spinal fusion (200,000 US)Putty for BMP delivery

Nucleus Pulposus (300,000 US) Meniscectomy 875,000 USRepair 64,000US

Assuming ASP of $3K the annual US market

potential for the above indications is $3.75B.

So

urc

e: M

ed

tech

In

sig

ht

Potential Strategic Partners

23

Tendon Repair Applications

24

Quadriceps tendon rupture

Rotator cuff repair

Biceps tendon

Patellar tendon rupture

Achilles tendon tear

No tissue repair technology currently exists for large tendon and

muscle defects that is natural, strong, large, has good suture retention

and provides enhanced wound healing.

Extracellular Matrix Patches for Tendon Repair

„ Indication: rotator cuff repair augmentation

„ Rationale:‟ Natural, three-dimensional and mechanically robust

scaffold that may have ability “off-load” the repair

‟ A chemically and structurally instructive environmentfor host cells leading to integration and the formationof bridging tissues

25

Commercial Scaffolds for Tendon & Ligament Repair

26

Representative Stress-Strain Curves for Commercially Available ECM Scaffolds

274mm wide by 300mm long strips were tested (Aurora et al.,2007)

Raw Material DistributionCollage rh™

„ Signed Distribution agreement with FUNAKOSHI Co., Ltd.(Japan), a leading distributor for the R&D market.

„ Distribution agreement with WAKO (Japan) is currentlyunder negotiation.

„ Initiated discussions with Sigma Aldrich regarding addingCollage rh™ to their products catalog.

28

StatusPatent NameNo

National Phase

Allowed: EP, SA, NZ, SG

Priority Sep 2004

COLLAGEN PRODUSING PLANTS AND METHODS OF GENERATING AND USING SAME

1

National Phase

Priority Oct 2007

METHODS OF PROCESSING RECOMBINANT PROCOLLAGEN2

National Phase

Priority Nov 2007

PREPARATION OF POLYSACCHARIDE COMPOSITES WITH RESILINPROTEIN COMPOSITIONS

3

PCT Application – Apr 2009METHODS OF GENERATING PROCOLLAGEN AND METHODS UTILIZING PROCOLLAGEN TO ACCELERATE ENHANCE WOUND HEALING AND/OR PREVENT SCAR FORMATION

4

Provisional - Nov 2009METHOD OF GENERATING COLLAGEN FIBERS5

Robust Intellectual Property

29

Board and Management

Senior Management:„ Yehiel Tal, CEO

Regentis Biomaterials, ProChon Biotech, Kulicke & Soffa.

„ Oded Shoseyov, Prof., CSO, Co-FounderHebrew University of Jerusalem.

„ Alon Bloomenfeld, CFOBiomedix, Runcom technologies, BrightCom Technologies.

„ Noa Lapidot, PhD, EVP Operations & Dev.Intec Pharma, Sol-Gel Technologies, Electric Fuel, Teva.

„ Hagit Amitai, PhD, VP R&DCompugen, QBI, Quantomix , InterPharm-Serono.

30

Board of Directors:„ Efi Cohen-Arazi, Chairman

Intec Pharma, Amgen, Immunex, Serono.

• Ran NussbaumPontifax VC.

• Elad NaggarBiomedix Incubator, Endogun, MindGuard.

• Oded Shoseyov, Prof.Co-Founder.

• Alon Dumanis, PhDDocor International Management.

• Liron EderyR.E.G.L.

• Eyal BigonTFG.

Consultants & Medical Advisors

Consultants:„ Avram Hershko, Prof. Technion IL, Nobel Laureate in Chemistry (2004)„ Abhay Pandit, Prof. National University of Ireland, Galway, Therapeutic Factors„ Ben Walthall, PhD Ex VP Zimmer, Tendon, Cartilage & Bone Repair „ Kathe Derwin, PhD Cleveland Clinic, Rotator Cuff„ Arthur Gertzman, Ex VP MTF ‟ Bone Void Fillers & Polymers

31

Medical Advisors:„ Prof. Ofer Levy, MD Royal Berkshire Hospital UK, Shoulder & Elbow„ Lawrence Gulotta, MD Hospital for Special Surgery US, Rotator Cuff„ Gabi Agar, MD Assaf Harofeh Hospital IL, Knee (ACL, Cartilage, Meniscus)„ Eran Tamir, MD Assaf Harofeh Hospital IL, Wound Care

Financials

„ Became public on May 2010, raising ~14.5M NIS

„ Cash status as of May 31st 2010 ~20M NIS

„ OCS grant of 3.9M NIS for 2010 R&D projects

„ Average monthly expenses 1.6M NIS

„ Applying for additional grants

„ Expected initial income during 2011

32

Use of Proceeds

„ Technology research and development

„ New products development

„ Regulatory and clinical activities

„ Increasing production capacity

„ Ongoing row material production

33

The CollPlant Opportunity

„ Unique, protected technology„ Clear, Unmet Medical Need„ Large, growing multi-billion $ market„ Large scale production capability of recombinant human collagen

„ Platform for biomaterials, regenerative medicine and drug delivery

„ Rich and attractive pipeline„ Experienced & knowledgeable leadership Team

34

Thank You

www.collplant.com

35